Relmada Therapeutics, Inc. (RLMD)

Market Cap	291.13M
Revenue (ttm)	n/a
Net Income (ttm)	-56.17M
Shares Out	73.33M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	957,833
Open	3.930
Previous Close	3.950
Day's Range	3.901 - 4.320
52-Week Range	0.240 - 4.340
Beta	0.83
Analysts	Hold
Price Target	1.00 (-74.81%)
Earnings Date	Nov 13, 2025

About RLMD

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Summary

According to 2 analysts, the average rating for RLMD stock is "Hold." The 12-month stock price target is $1.0, which is a decrease of -74.81% from the latest price.

Price Target

$1.0

(-74.81% downside)

Analyst Consensus: Hold